An Anti-VEEV BBB-penetrating bispecific provides comparable therapeutic protection in the context of VEEV-TrD infection in vivo
- Sandia National Laboratories (SNL-CA), Livermore, CA (United States)
- Research Organization:
- Sandia National Laboratories (SNL-CA), Livermore, CA (United States)
- Sponsoring Organization:
- Defense Threat Reduction Agency; USDOE National Nuclear Security Administration (NNSA)
- DOE Contract Number:
- NA0003525
- OSTI ID:
- 2999385
- Report Number(s):
- SAND2024-13279C; 1758678
- Country of Publication:
- United States
- Language:
- English
Similar Records
Characterization of SNL identified BBB-penetrating moieties (BBB PMs) for delivery of therapeutic cargo to the CNS.
Characterization of novel BBB-penetrating nanobodies for delivery of therapeutic cargo to the CNS
Therapeutic efficacy of a potent anti-VEEV antibody is contingent on humoral and cell-mediated cytotoxic immunity.
Conference
·
Sat Oct 01 00:00:00 EDT 2022
·
OSTI ID:2006120
Characterization of novel BBB-penetrating nanobodies for delivery of therapeutic cargo to the CNS
Conference
·
Sat Dec 31 23:00:00 EST 2022
·
OSTI ID:2588934
Therapeutic efficacy of a potent anti-VEEV antibody is contingent on humoral and cell-mediated cytotoxic immunity.
Conference
·
Sat Oct 01 00:00:00 EDT 2022
·
OSTI ID:2005942